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Drug allergies are an important consideration in clinical practice, as
they are associated with substantial
morbidity, mortality, and increased
healthcare costs. Adverse drug reactions are the most common iatrogenic illness, with 3 to 6% of all
hospital admissions occurring because of an adverse drug reaction,
and 6 to 15% of all hospitalized
patients experiencing an adverse
drug reaction.1,2
The classical division of adverse
drug reactions classifies reactions
into type A and type B (Table 1).
Immune-mediated reactions account for 5 to 10% of all drug reactions and constitute true drug hypersensitivity, with IgE mediated drug
allergies being included in the type
B category. The World Allergy
Organization defines a drug allergy
as a hypersensitivity reaction for
which a definite immunological
mechanism, either IgE or T-cell
mediated, is demonstrated.1 Reactions that clinically resemble an
allergy but do not have a proven
immunological cause should be
classified as a non-immune hypersensitivity reaction. Table 1 differentiates between the various types
of immunologic reactions.
Certain risk factors have been identified which play an important role
in drug hypersensitivity. In order

for a medication to be immunogenic
(ie, cause an allergic response), it
must have a certain molecular weight
and structural complexity (eg, large
protein), or it must act as a hapten, a
molecule that requires binding to a
carrier protein to elicit an immune
response. While some medications
are intrinsically reactive, others can
become immunogenic by binding to
immune receptors, T cell receptors,
and major histocompatibility complex (MHC) peptides.1,2 Medications
administered by the intravenous (IV),
intramuscular (IM), or topical routes
are more likely to elicit a response
than those taken orally. Patient populations at risk for hypersensitivity
reactions include females; patients
with human immunodeficiency virus
(HIV), systemic lupus erythematosus
(SLE), cystic fibrosis (CF), or
asthma; and those who have experienced previous hypersensitivity reactions to a chemically related medication. Table 2 lists other risk factors
for experiencing adverse drug reactions, both immune and non-immune.
Gell and Coombs identified and classified the various types of immunemediated drug hypersensitivity reactions. Each type varies in its mechanism, immune mediators, clinical
presentation, and timing in relation
to drug exposure. Table 3 describes
each of these reactions and provides
examples of particular drug reactions.
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Table 1: Immunologic and Nonimmunologic Drug Reactions
Immunologic
Type I reaction
IgE mediated

Example
Anaphylaxis from beta-lactam
antibiotic

Type II reaction
cytotoxic

Hemolytic anemia from
penicillin

Pharmacologic side effect

Dry mouth from
antihistamines

Type III reaction
immune complex

Serum sickness from antithymocyte globulin

Secondary pharmacologic
side effect

Thrush while taking
antibiotics

Type IV reaction
delayed, cell-mediated

Contact dermatitis from
topical antihistamine

Drug toxicity

Hepatotoxicity from
methotrexate

Specific T-cell activation

Morbilliform rash from
sulfonamides
Stevens-Johnson syndrome
Toxic epidermal necrolysis

Drug-drug interactions

Seizure from theophylline
while taking erythromycin
Seizures from excessive
lidocaine

Fas/Fas ligand-induced
apopotosis
Other

Drug-induced, lupus-like
syndrome
Anticonvulsant
hypersensitivity syndrome

Nonimmunologic

Type A (predictable and dose dependent)

Drug overdose

Type B (unpredictable and not dose-dependent)
Pseudoallergic
Idiosyncratic
Intolerance

Anaphylaxis: Anaphylaxis is a severe, life-threatening type I allergic
reaction. Approximately 1.2 to 16.8%
of the population may experience an
anaphylactic reaction (3.3 to 43 million Americans), with around 1500
deaths occurring annually in the
United States. Anaphylactic reactions
occur when a foreign antigen interacts with IgE receptors on cell surfaces of mast cells and basophils.
Receptor binding triggers release of
histamines and other bioactive mediators that, in turn, cause smooth
muscle spasm, bronchospasm, mucosal edema, and inflammation.
Anaphylactoid reactions are caused
by release of the same mast cell and
basophil mediators by non-IgE
mechanisms. Symptoms of both anaphylaxis and anaphylactoid reactions
can range from weakness, dizziness,
congestion, and sneezing to upper
respiratory tract obstruction, hypotension, vascular collapse, cardiovascular arrhythmias, and/or cardiac arrest.4 The true incidence and prevalence figures for anaphylaxis are hard

Example

to identify as there is no standard
diagnostic criteria. Diagnosis can
encompass reactions ranging from a
systemic allergy to one that is always severe and life-threatening.
Patients at highest risk are also hard
to identify, as the best predictor for
potential anaphylaxis is a patient
with a documented history of previous anaphylactic reactions. Antibiotics and radiocontrast media cause
the greatest amount of anaphylactic
reactions by medications. Table 4
reviews various medications associated with anaphylactic reactions.4
Of all classes of medications, antibiotics are the most likely to cause
hypersensitivity reactions. Antibiotic allergies are variable in the
type and severity of the reaction,
organ system affected, and crossreactivity to other agents. Approximately 2% of reactions to antibiotics are cutaneous, with the most
common manifestations being skin
eruptions, urticaria, and pruritus.
Such reactions most often occur
days to weeks after initial exposure;

Anaphylactoid reaction after
radiocontrast media
Hemolytic anemia in a patient
with G6PD deficiency after
primaquine therapy
Tinnitus after a single dose of
aspirin

Table 2. Patient Risk Factors
for Adverse Drug Reactions
General drug reactions
(non-immune related)
▪ Female gender
▪ Serious illness
▪ Renal insufficiency
▪ Liver disease
▪ Polypharmacy
▪ HIV infection
▪ Herpes infection
▪ Alcoholism
▪ Systemic lupus erythematosus
Hypersensitivity drug reactions
(immune related)
▪ Female gender
▪ Adult HIV infection
▪ Concomitant viral infection
▪ Previous hypersensitivity to
▪ chemically-related drug
▪ Asthma
▪ Use of beta blockers
▪ Specific genetic polymorphisms
▪ Systemic lupus erythematosus
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Table 3: Classification of Hypersensitivity Reactions
Gell-Coombs
Classification
Type I
immediate
hypersensitivity

Time of
Onset
< 1 hour

Type II
late cytotoxic
reactions

> 72 hours

Immune cytopenia; hemolytic
anemia, thrombocytopenia, or
neutropenia; vasculitis

Type III
immune complex
reactions

> 72 hours
(1 to 3 weeks
after drug exposure)

Serum sickness, drug fever,
rash, arthralgias, lymphadenopathy, urticaria,
glomerulonephritis, vasculitis

Type IV
delayed
cell-mediated

> 72 hours

Contact dermatitis,
maculopapular drug rash

similar reactions may develop much
sooner upon secondary exposure to
the medication. In contrast, hypersensitivity syndromes and anaphylaxis can occur almost immediately
after drug exposure and may result in
more significant signs and symptoms
such as fever, eosinophilia, bronchoconstriction, and hypotension.
Penicillin allergies: Penicillin is the
most common cause of drug-induced
anaphylaxis, with an incidence of
approximately 0.004% to 0.015%
(1:10,000 to 1:5000 courses of therapy). Additionally, penicillin is the
most frequently reported drug allergy
by patients. While around 10% of
patients report a history of penicillin
allergy, the true incidence of penicillin allergy in these patients is often
less.6
Penicillin is the best characterized
antibiotic in terms of mechanism of
hypersensitivity reactions. Antibodies formed in response to penicillin
are directed at the beta-lactam ring.
Penicillins bind spontaneously to endogenous and exogenous proteins,
forming hapten carriers that become
immunogenic and trigger type I hy-

Clinical Manifestation

Mechanism

Anaphylaxis, urticaria, angioedema, wheezing, laryngeal
edema, bronchospasms, hypotension

Antibiotic-specific IgE
antibodies binding to mast
cells with release of histamine and inflammatory
mediators
Specific IgG or IgM antibodies plus complement
directed at drug-hapten
coated cells
Tissue deposition of IgG
and IgM immune complexes with complement
activation and
inflammation
MHC presentation of drug
molecule to T cells with
cytokine and inflammatory
mediator response

persensitivity reactions. Penicillin
is degraded into products termed
major and minor antigenic determinants. The major penicillin determinant, benzylpenicilloyl
polylysine, is used for skin-prick
testing followed by intracutaneous
testing to detect allergen-specific
IgE antibodies.2,5 Approximately
60% of patients with positive skin
tests will have an allergic reaction
when penicillin is administered.6,9
Data suggests that in patients with
negative skin test results, penicillin

Example
Penicillin; fatal outcome in 1:50,000 to
1:100,000 treatment
courses
Anticonvulsants

Diuretics

Topical antihistamines

administration has a 4% risk of immediate reaction, similar to that of
the general population.5
For patients who have IgE antibodies
to penicillin but must receive therapy
for certain conditions (eg, neurosyphilis), desensitization therapy may
be considered. These protocols are
performed in a hospital setting by
giving increasing amounts of drug
over a period of hours until a therapeutic dose is reached.5 A typical
starting dose is in micrograms and is

Table 4. Selected Medications Causing Anaphylaxis
Chemotherapeutic
Agents

Antibiotics

▪
▪
▪
▪
▪
▪
▪
▪

Penicillin and derivatives
Cephalosporins
Tetracycline
Chloramphenicol
Sulfonamides
Ciprofloxacin
Nitrofurantoin
Vancomycin

▪
▪
▪
▪
▪

Asparaginase
Vincristine sulfate
Cyclosporine
Methotrexate
Fluorouracil

Miscellaneous

▪ Aspirin
▪ Nonsteroidal anti▪
▪
▪
▪
▪
▪
▪
▪
▪

inflammatory drugs
Allergy extracts
Immune globulin
Insulin Heparin
Vaccines
Dextran
Opiates
Protamine sulfate
Local anesthetics
Glucocorticosteroids
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doubled every 15 to 30 minutes;
therapeutic doses can be reached in 4
to 5 hours. During this time, the patient should be monitored and given
antihistamines and inhaled betaagonists for urticaria and bronchospasm, respectively.5 The procedure
may resume at the last tolerated dose
if mild flushing or urticaria occurs;
however, an alternative antibiotic
should be selected if the patient experiences a severe reaction such as
hypotension or severe bronchospasm.
Cephalosporin allergies: Like other
antibiotics, cephalosporins tend to
produce allergic reactions manifesting as rashes (1 to3%).7 Antigenic
cross-reactivity between penicillins
and cephalosporins may occur in certain patients, as these antibiotics have
similar chemical configurations.
Varying degrees of cross-reactivity
between cephalosporins and penicillins have been reported in the literature, confounded by the lack of a
standardized definition of drug allergy and absence of confirmed diagnosis by IgE antibody presence.
The most quoted study comparing
cephalosporin cross-reactivity in patients with penicillin allergies examined records of 15,708 patients in
clinical trials who received cephalothin, cephaloridine, cephalexin,
cefazolin, or cefamandole. Of the
patients with a history of allergy to
penicillin, 8.1% had an allergic reaction to the cephalosporin, as compared with 1.9% of patients who did

not have a history of penicillin allergy.6 However, many of these
first-generation cephalosporins contained trace amounts of penicillin as
a result of their manufacturing process. Additionally, many of the patients with self-reported history of
penicillin allergy did not have confirmatory skin testing. As patients
with penicillin allergies have a 3fold higher rate of allergic reactions
to any drug, even those structurally
unrelated, concomitant allergy may
not be due to cross-reactivity.6,9
While penicillin allergy depends on
the beta lactam ring structure,
cephalosporin allergies develop
more from their side chain molecular structure. The side chains of
cephalothin and cephaloridine
closely resemble penicillin; the side
chains of cefadroxil, cephalexin,
cefaclor, cephradine, cefprozil, cefatrizine, and cefadroxil resemble
those of ampicillin and amoxicillin.6,7,9 Administration of these
medications have a 0.5% to 6.5%
greater likelihood of producing
allergic reactions among patients
with a history of allergy to penicillin or amoxicillin, respectively.6
Other cephalosporins are unlikely
to produce allergic reactions in patients with a history of reactions to
compounds with different molecular structures (Table 5). Crossreactivity is low between penicillin
and second-, third-, and fourthgeneration cephalosporins.9

Recently, the American Academy of
Pediatrics (AAP) published evidencebased guidelines that advocate using
certain cephalosporins in patients
with penicillin allergies for the treatment of acute bacterial sinusitis and
acute otitis media.6 Reactions that
are IgE mediated, manifested as
bronchospasm, angioedema, hypotension, urticaria, or a pruritic rash, are
likely to become more severe with
time. Guidelines recommend in patients with a history of IgE-mediated
reactions that alternative therapies
should be considered. However, patients who report nonurticarial and
non-pruritic rash or any type II, III,
or IV reactions may be given cephalosporins with caution.6
Carbapenem and monobactam allergies: Carbapenems differ from
penicillins in they are unsaturated
and contain a carbon atom instead of
sulfur.8 Carbapenem allergy is present in about 11% of penicillin allergic patients and less than 3% of nonallergic patients.9,12
One recent review noted an overall
frequency of carbapenem hypersensitivity in 9 to11% of penicillin allergic
patients based on a retrospective review.12 The authors noted that carbapenem therapy should be avoided
in patients in documented type I hypersensitivity reactions; however, it
may be considered for infections with
multidrug-resistant organisms in patients with a less clearly defined allergic history. These patients should

Table 5. Chemical Structure of 7-Position (R1) Side Chain Penicillin and Cephalosporins
▪
▪
▪
▪

Similar Structure, Possible Cross-Reactivity Within Group
Penicillin G
▪ Ampicillin
▪ Cefepime
Cefoxitin
▪ Amoxicillin
▪ Cefotaxime
Cephaloridine
▪ Cefaclor
▪ Cefpodoxime
Ceftizoxime
Cephalothin
▪ Cefadroxil
▪
Ceftriaxone
▪ Cefatrizine

▪ Cefprozil
▪ Cephalexin
▪ Cephradine

Dissimilar Structure, Unlikely Cross-Reactivity
▪ Cefamandole
▪ Cefotetan
▪ Cefazolin
▪ Ceftazidime
▪ Cefdinir
▪ Ceftibuten
▪ Cefixime
▪ Cefuroxime
▪ Cefonicid
▪ Cephapirin
▪ Cefoperazone
▪ Moxalactam
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be closely monitored for signs and symptoms of drug hypersensitivity and treated with appropriate therapies should a
reaction occur.
Aztreonam is a monocyclic beta lactam, also known as a monobactam, with the same side chain as ceftazidime.8 No specific IgE antibodies have been identified for aztreonam. While cross-reactivity between aztreonam and ceftazidime has
been reported, many patients with penicillin allergies have been able to tolerate aztreonam in previous studies.
Conclusion: In summary, adverse events, particularly drug allergies and anaphylaxis, in response to beta lactam antibiotics are common and well documented. Most adverse events from antibiotics manifest as cutaneous reactions, resulting
in skin eruption, urticaria, and pruritus. More serious reactions such as anaphylaxis may occur and result in respiratory,
cardiovascular, and gastrointestinal symptoms. Penicillin is responsible for approximately 75% of fatal anaphylaxis reactions in the United States, causing approximately 500 to 1000 deaths per year.4 Structurally related cephalosporins
may provoke allergic and even anaphylactic reactions in penicillin allergic patients; however, true risk for crossreactivity has not been clearly defined. Patients experiencing a non-urticarial rash to penicillins may be cautiously given
other beta-lactam antibiotics; however, those patients with documented IgE-mediated allergy or anaphylaxis should receive alternative therapies.
References available upon request.

Glossary of Terms
Anaphylaxis

Anaphylactoid reaction
Beta lactam

Cross-reactivity / cross-sensitivity
Drug allergy
Drug hypersensitivity
(Adverse) Drug reaction
Type A reaction
Type B reaction

acute mucocutaneous signs (pruritus, flushing, urticaria, angioedema) coupled with
respiratory obstructive symptoms (edema, bronchospasm), cardiovascular symptoms
(hypotension), gastrointestinal symptoms (nausea, vomiting, diarrhea); caused by the
interaction of a foreign antigen with IgE receptors on basophils and mast cells
symptoms closely resemble an anaphylactic reaction; caused by the release of mast cell
and basophil mediators triggered by non-IgE events
antibiotics in the penicillin, cephalosporin, carbapenem, and monobactam categories;
with the exception of the monobactam aztreonam, these drugs all contain a 5membered ring attached to a beta-lactam ring
after production of IgG and IgM in response to a specific antigen, these antibodies may
react to structurally similar antigens; does not include coincidental IgE-mediated drug
allergy
IgE- or T-cell-mediated response to a drug agent in a sensitized patient
immune-mediated response to a drug agent in a sensitized patient
all adverse events related to drug administration, regardless of etiology
dose-dependent and predictable reaction to a drug;
majority of all drug reactions
not dose-dependent, unpredictable;
approximately 5 to 15% of all drug reactions; includes hypersensitivity reactions

Virtual Drug Information Database (VDI)
Search pre-answered questions regarding disease therapy management, compatibility/stability,
compounding formulations, drug interactions, or other general drug information questions.
The VDI is available at: www.muschealth.com/vdiSearch/Login.aspx? (Use NetID login/
password for access). If you are unable to find the information needed, contact the Drug
Information Service for assistance.
MUSC Drug Information Service
Phone: 792-3896 / E-mail: druginfo@musc.edu
Monday - Friday (9:00 AM - 5:30 PM)
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FORMULARY UPDATE FOR JANUARY 2010
In January 2010, the Pharmacy
and Therapeutics Committee approved the actions listed below. The
formulary effective date was February 17, 2010, unless otherwise noted.
ADDED WITH RESTRICTION:
Prasugrel (Effient™) Prasugrel is a new platelet inhibitor
which showed greater efficacy than
clopidogrel in preventing secondary
ischemic events in acute coronary
syndrome (ACS) patients undergoing
percutaneous coronary intervention
(PCI); however, more bleeding
events were reported versus clopidogrel. It may have a therapeutic use
in patients resistant to clopidogrel;
however, it is more expensive. Prasugrel will be restricted to the attendings or fellows on the Cardiology
service. A preprinted order form is
being created; once the order form/
CPOE form has been finalized, a formulary effective date will be announced.
Tablets: 5 and 10 mg

ADDED:
Hylan G-F 20 (Synvisc One®)
Hylan G-F 20 is a high molecularweight hyaluronan. It is as efficacious as other hyaluronan products
available, including Hyalgan®, the
current product on the formulary.
Due to decreased number of injections, Synvisc One® may increase
patient satisfaction and offer a costsavings advantage.
Injection: 10-mL syringes
(48 mg/6mL of Hylan G-F 20)

CHANGE IN RESTRICTION:
Daptomycin (Cubicin®)
Per the Anti-infective Subcommittee,
it was recommended to include Hematology/Oncology as an approved
service for daptomycin per clinical
guidelines utilizing the febrile neutropenia order form.

CHANGE IN AUTOMATIC
THERAPEUTIC SUBSTITUTION
(ATS) PROTOCOL:
Per the Anti-infective Subcommittee,
the hemodialysis dose for doripenem
on the ATS protocol was increased to
500 mg q24h, dosed after dialysis on
days of dialysis.
UPDATED ATS PROTOCOL:
The ATS protocol for the antihistamine class is being updated to include levocetirizine (Xyzal®).
NOT ADDED:
Norfloxacin (Noroxin®)
Norfloxacin is recommended for the
prophylaxis of spontaneous bacterial
peritonitis (SBP) in some national
guidelines, but current information
do not relate efficacy over standard
treatments like ciprofloxacin or
trimethoprim/sulfamethoxazole. Per
the Anti-infective Subcommittee, it
was recommended that norfloxacin
not be added, since other proven
therapies (eg, ciprofloxacin) are already on the formulary.
Dronedarone (Multaq®)
Dronedarone is a noniodinated benzofuran derivative structurally and
mechanistically related to amiodarone. Dronedarone may interact with
other medications that undergo metabolism via the CYP3A system.
Clinical studies have shown increased mortality in patients with
Class IV or decompensated Class II
or III heart failure, leading to a blackbox warning and contraindicated use
in this population. Its efficacy compared with other antiarrhythmics,
specifically amiodarone, or its current place in therapy is still unknown.
The monthly cost of dronedarone is
significantly higher than that of its
competitor amiodarone. At this time,
it was not felt that dronedarone had
enough data to warrant addition to
the formulary.

LINE EXTENSIONS
▪ Rotavirus vaccine (Rotarix®)
1-mL injection

▪ Lidocaine (Xylocaine® MPF) 1%
DUOFIT unit

▪ Selegiline (Eldepryl®) 5-mg capsule
▪ Efavirenz (Sustiva®) 50-mg capsule
▪ Betamethasone (Valisone®) cream
DELETIONS
▪ Chlordiazepoxide (Librium®)
10-mg capsule

▪ Trimethobenzamide (Tigan®)
▪
▪
▪
▪
▪
▪
▪
▪

300-mg capsule 100-mg/mL injection
Fluocinolone cream, solution, ointment
Geri-silk® 2-oz bath oil
Lanolin (anhydrous) 1-ointment
Thera-Derm® 8-oz lotion
Acetic acid/aluminum acetate
(Domeboro®) solution
Selegiline (Eldepryl®) 5-mg tablet
Efavirenz (Sustiva®) 100-mg capsule
Betamethasone (Diprolene®) cream

CHARTS, GUIDELINES, AND
ORDER FORMS:
The Febrile Neutropenia Guidelines
and preprinted order form have been
updated to reflect changes to firstline therapies, as well as the inclusion
of daptomycin for VRE colonized
patients meeting criteria.
The Sepsis preprinted order forms
have been updated to include
changes/clarification of a documented penicillin allergy, as well as
new vancomycin dosing recommendations.
The following policies have been
updated and will be posted online:

▪
▪
▪
▪
▪
▪
▪

C26 - Sample Medication Policy
C60 - Patient Care Unit Refrigerators,
C61 - Medication Administration,
C68 - Standing Orders,
C78 - Medication Orders
C82 - Formulary Management
C159 - Continuous Infusion Policy.

